Nexstim Oyj - Managers' Transactions

Company announcement, Helsinki, 25.5.2020 AT 8 PM (EET)

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD),  announces manager’s transactions as follows:

Person subject to the notification requirement

Name: Kaikarhenni Oy

Position: Closely associated person

(X) Legal person

(1):Person Discharging Managerial Responsibilities In Issuer

Name: Leena Niemistö

Position: Member of the Board

Issuer: Nexstim Oyj

LEI: 743700S7ZI0LNMHZ6Y27

Notification type: INITIAL NOTIFICATION

Reference number: 743700S7ZI0LNMHZ6Y27_20200525112333_10

____________________________________________

Transaction date: 2020-05-22

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000354162

Nature of the transaction: SUBSCRIPTION

(X) Executed under portfolio or asset management

Transaction details

(1): Volume: 52,113,756 Unit price: 0.006 EUR

Aggregated transactions

(1): Volume: 52,113,756 Volume weighted average price: 0.006 EUR

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+ 358 50 326 4101
[e-mail]

Sisu Partners Oy (Certified Adviser)
Jussi Majamaa
+ 358 40 842 4479
[e-mail]

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden.

For more information please visit www.nexstim.com

Attachment

• Nexstim_CA_Johdon liiketoimet_25 5 2020 ENG